Presentation is loading. Please wait.

Presentation is loading. Please wait.

AMCo – new beginnings 20 th November 2013. John Beighton Medical Rep/Regional Manager - Smith Kline and French UK – 1981-1990 Various sales and marketing.

Similar presentations


Presentation on theme: "AMCo – new beginnings 20 th November 2013. John Beighton Medical Rep/Regional Manager - Smith Kline and French UK – 1981-1990 Various sales and marketing."— Presentation transcript:

1 AMCo – new beginnings 20 th November 2013

2 John Beighton Medical Rep/Regional Manager - Smith Kline and French UK – Various sales and marketing jobs – SmithKline Beecham UK – Commercial Director – APS Berk/Teva UK – Managing Director Teva UK – VP Global Business Optimisation – Teva Pharmaceutical Ind. – 2009 – 2010 CEO AMCo – 2010 to date Presenter

3 Company Origins “G word” Mar-12 Aug-12 Oct-12 Jan-13 £465m£367m Rebranding Refinancing

4 % 38 £106 million 2012 Sales Revenues in the United Kingdom Countries with commercial presence Established Brands and Generics Virtual Business Model (R&D, Manufacturing outsourced) Established 1991, Headquarters in South London Acquired by Cinven (Private Equity) August 2012 for £465 million Rx Mercury Pharma

5 % 100+ £109 million 2012 Sales Revenues in the United Kingdom Countries with commercial presence Established Brands and Generics Virtual Business Model (R&D, Manufacturing outsourced) Established 2002, Headquarters East of London. Acquired by Cinven (Private Equity) August 2012 for £367 million Rx Amdipharm

6 2013 Expected revenues (15% Growth) Amdipharm Mercury (AMCo) % 112 £248 million Rx Established Brands and Generics Virtual Business Model (R&D, Manufacturing outsourced) Revenues in the United Kingdom Countries with commercial presence Combined group rebranded AMCo in March 2013 UK Office to be relocated to Central London

7 Macrodantin, Furadantin, Macrobid, Furabid nitrofurantoin £18m 18 Countries figures quoted are 2013 forecast revenues Eltroxin levothyroxine £27m 13 Countries Liothyronine liothyronine £10m 10 Countries Neomercazole carbimazole £12m 20 Countries Fucithalmic fusidic acid £26m >90 Countries Hygroton chlortalidone £5m 12 Countries Ludiomil maprotiline £3m 25 Countries Cafergot ergotamine £2m 26 Countries Diamox acetazolamide £5m 27 Countries Hytrin terazosin £5m 21 Countries Erythrocin erythromicin £16m 32 Countries Akineton biperiden £7m 21 Countries Transact flurbiprofen £8m 2 Countries Acquisition History

8 Management Team Guy Clark Strategic Development Robert Sully General Counsel Vikram Kamath Finance Director John Beighton CEO John Cowell Human Resources Bharat Karbal Medical & Regulatory Jane Hill UK Commercial Karl Belk Global Operations Simon Tucker International Commercial Brian McEwan Managing Director Amdipharm Peter van Tiggelen CFO

9 Sales History by Company 2010 to 2013 est. Company Performance Millions

10 Top 10 Molecules (Percentage of 2012 revenue) Levothyroxine 11% Erythromicin 8% Nitrofurantoin 7% Flurbiprofen 5% Codeine + paracetamol 5% Biperiden 4% Liothyronine 4% Carbimazole 4% Prednisolone 4% Cyclizine 3%

11 AMCo Strategy Consolidate strong position in UK – Off-patent brands and niche products

12 UK Commercial Team Jane Hill UK Commercial Director Jeremy Devaney Hospitals Jenna Pritchard National Accounts Neil Cook Promoted Products

13 AMCo Strategy Focus on 5 Business Action Plans – Operational Excellence – Culture and Integration – Compliance – Quality and Reputation – International Excellence – Strategic Growth

14 Global Coverage AMCo offices/direct presence Distributor network >50% of sales in UK

15 International Excellence AMCo offices/direct presence Distributor network Target markets – direct presence

16 Licensing Development Acquisition Dedicated business development team focused on driving revenue and profit growth Brands Primary & Secondary Care Low Competition Stable Revenues and Profit Multiple Markets Growth Opportunities Geographic Expansion Companies & Products Company acquisitions Build out in Target Markets Portfolio Optimisation Distributor consolidation Therapeutic Focus Primary & Secondary Care Ophthalmology Endocrinology Urology Infectious Diseases Pain & Anaesthesia Strategic Growth Generics Primary & Secondary Care Low Competition Barriers to Entry Branded Generics Sustainable Pricing

17 Strategic Development Activity Portfolio Optimisation – registering existing AMCo products into new markets where the product isn’t currently registered or sold, and using the existing manufacturers to make the product Product Development – creating new products with a contract development partner, whereby AMCo retains full ownership rights to the product, and freedom to choose who to manufacture the product In-Licensing – buying the rights to sell a third party’s product in a defined territory, and agreeing for the licensor to supply the product to AMCo for an agreed period of time (typically 5 years) Product Acquisitions – buying the permanent rights to own an existing product, in a defined territory (sometimes global e.g. Fucithalmic). The seller may wish to continue making the product, but more often would require AMCo to find a new supplier within 2-3 years

18 United Kingdom No. 1 Croydon Addiscombe Road Croydon CR0 0XT +44 (0) Committed to being a socially responsible company, we support: Ireland 102 Block B The Crescent Building Northwood Santry Dublin (0) India 101 Vedanta 779 Makwana Road Marol Andheri East Mumbai


Download ppt "AMCo – new beginnings 20 th November 2013. John Beighton Medical Rep/Regional Manager - Smith Kline and French UK – 1981-1990 Various sales and marketing."

Similar presentations


Ads by Google